A nimal experiments and human trials have produced growing evidence implicating the gut microbiota and its metabolites in cardiovascular disease. High-throughput sequencing technologies and metabolomics opened a new avenue to decipher the interrelationship between lifestyle, diet, pharmacotherapy, and the gut microbiome. Microbiomes from diseased and nondiseased individuals differ, exhibiting a dysbiotic, as opposed to eubiotic, state as shown for several inflammatory, cardiovascular, and metabolic disorders, including hypertension. We investigated the interconnections involved and summarized here how exogenous factors such as nutrition, disease risk factors, drug therapies, and other variables could affect the microbiome and the homeostasis of its metabolites with a special focus on short-chain fatty acids. The research field is important for understanding and countering increased disease susceptibility and cardiovascular risk.
Our planet's age is estimated at about 4 billion years; factors enabling life existed perhaps 3 billion years ago. Our predecessors were unicellular, probably not bacteria but perhaps archaea. However, a lively interaction between unicellular organisms and our ancestors undoubtedly occurred. The existence of microbes numbering in the trillions traveling within us leads to an understanding of the host-microbiome whole as the human holobiont (Table 1 ). Holobionts are assemblages of different species that form ecological units. Ours is a mammal harboring bacteria, viruses, protozoans, archaea, and fungi. These fellow travelers exist on all mucous membranes. In this review, we focus here on the gastrointestinal tract. Our knowledge about the abundance and functionality of bacteria at different sites in our body advanced in the last decade to permit insights into what these microbes actually are doing. Collectively within a host, the microbes are referred to as its microbiota (Table 1) , with their genes or collective genomes considered their microbiome ( Table 1 ). The 70 kg reference prototype individual harbors 3.8×10 13 bacteria from 500 to 1000 different species, approximately as many as there are human cells (3.0×10 13 ) in the body. The microbiome makes up about 1% to 3% of the host's body mass (same as the liver) and encodes for over 4 million separate genes. 1 Unlike the human genome, the microbiome, often considered our second genome, is quite flexible on short time scales. The composition of the gut microbiota shows a great deal of interindividual variability. 2 Therefore, the gut microbiota of each individual is now seen as an unique endocrine-like organ, generating and affecting the degradation and uptake of circulating metabolites, which affect host physiology, including within immunity, neuronal development, and metabolism. The metabolites trigger responses not only locally in the respective microenvironment but also at distant target organs. 3 Overcoming the limitations of bacteria culture-based technologies, the introduction of high-throughput sequencing technologies (16S ribosomal RNA or shotgun DNA sequencing; Table 1 ) and various forms of comparative metabolomics now allows us to better determine microbiome diversity and function. As a result, our appreciation of how the microbiome contributes to disease has greatly increased. 4 Microbiomes from individuals with various diseases are in a dysbiotic state (Table 1) , whereas in nondiseased people, they exhibit a eubiotic state, as shown for several inflammatory, cardiovascular, and metabolic disorders, including hypertension. [5] [6] [7] [8] [9] In the absence of perturbations, a healthy intestinal microbial ecosystem is rather stable over years and lives in an equilibrium also with the surrounding community, in which the host lives. 10 However, drastic changes, such as the switch from breastfeeding to solid food in newborns, intestinal infections, or changes in environmental microbial exposure following global travel, can lead to transient or persistent gut microbiome alterations. 10, 11 These can affect not only the microbes and their metabolites but also the integrity of the epithelial barrier, such as in the case of leaky gut (Table 1) . Consequently, our symbionts (Table 1; friends) can be displaced by pathobionts (Table 1; foes), as a result of intestinal barrier dysfunction. The pathogens may even enter into the host bloodstream and cause low-or highgrade inflammation, triggering host responses including disease phenotypes. 12 We discuss gut microbiome-immune cell-host interactions including the role of microbiota-derived short-chain fatty acids (SCFA), in cardiovascular disease, the interplay of nutrition, and microbiota. We inspect the potential drug-microbiome interactions. Taken together, these bidirectional links are referred to as host-microbiome crosstalk.
Interaction Between Nutrients, Microbes, and Immune Cells Affects Health and Disease
The diet of many people worldwide has changed dramatically in the last decades, a state of affairs held responsible for the pandemic of obesity, metabolic disease, hypertension, and cardiovascular disease. The so-called Western Diet, now ingested almost universally, is rich in fat, sugar, salt, and calories but low in fiber. As our intestine is constantly exposed to ingested foods, microbes sense and subsequently may adapt to this dietary challenge. Thus, diet-microbiota interaction may influence health and susceptibility to disease. The microbiota changes are often not community-wide, but instead feature shifts in distinct microbial subpopulations. Nevertheless, consequences of the diet-induced shifts in the gut microbiota can be profound for the host epithelial cells and the gut immune system, in particular T cells. 5, [13] [14] [15] [16] Experimental and clinical evidence suggests that cells of the innate and adaptive immune system play pivotal roles in causing hypertension, thereby profoundly influencing cardiovascular disease progression. Typical features of a chronic inflammatory response in hypertension is the increased presence of effector memory T cells, T helper cell subtypes (Th17; producing IL [interleukin]-17), and Th1 (producing IFN [interferon]-γ) in cardiovascular target organs. [17] [18] [19] [20] In contrast, regulatory T cells (Treg), which typically produce high amounts of anti-inflammatory IL-10, limit tissue inflammation. 21 Various bacteria effectively communicate with different immune cell types, either directly or through metabolites that they produce. As a result, pro-or anti-inflammatory responses are evoked or modulated.
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Salt, Microbiome, and Hypertension
Asian populations consume high amounts of salt, ostensibly because of salty condiments such as soy sauce, whereas in the industrialized Western world, salt is predominantly obtained through the ingestion of processed products. [26] [27] [28] Although every ingested meal contains more or less salt, we have only recently begun to understand the impact of high-salt diets on the gut microbiome, when the salt reaches the intestinal compartment. Several recent studies have shed light on this area of research. Wang et al 29 found a shift in the Firmicutes-Bacteroidetes ratio with a greater abundance of Lachnospiraceae and Ruminococcus and decreased Lactobacillus operational taxonomic units in mice with high-salt dietary challenge. We recently also analyzed the microbiome of high-salt fed mice. 13 Using machine learning analysis trained to distinguish between high salt-treated and normal salt-treated mice, we classified 8 involved bacterial taxa to genus resolution. A Lactobacillus was the top predictor in the model. We isolated and sequenced it as Lactobacillus murinus. Quantitative polymerase chain reaction analysis confirmed a reduced L. murinus copy number upon high salt. Alongside with the depletion of L. murinus, high salt-fed mice had increased Th17 cells in their small and large intestine, spleen, and spinal cord. In parallel, high salt-fed mice developed salt-sensitive hypertension. 13 Previously, others and we have shown that high salt challenge also accelerates clinical multiple sclerosis symptoms of experimental autoimmune encephalomyelitis in mice facing myelin-specific antigens. 30, 31 These mice also show a pronounced Th17 response in the gut, spleen, and target organs, which was dependent on the serum glucocorticoid-regulated kinase-1. 31 Further, high salt also exacerbated experimental colitis associated with intestinal dysbiosis with a pronounced decrease of Lactobacillus abundance, a shift to a proinflammatory state in the colon, and intestinal barrier dysfunction with decreased tight junction molecules. Miranda et al 32 showed that high salt decreased several major SCFA producers such as Lachnospiraceae, Clostridiales, and Oscillospira as well as fecal butyrate levels, whereas other SCFA were unaltered. 
Human holobiont
The assembly of different species to form a unit. It is made up of the Greek terms for whole (hólos), life (bíos), and being (óntos). In the context of human, it means the symbiosis of the human organisms with bacteria, fungi, and virus.
Microbiota
The microbial taxa associated with humans.
Microbiome
The catalog of these microbes and their genes.
Metagenome
The sum of all genomes of species in a distinct community.
Symbiont
An organism living in a close biological relation with another organism.
Pathobiont
A potentially disease-causing symbiont.
Gut dysbiosis Perturbated microbial ecosystem compared with the healthy state or homeostasis (eubiosis) often associated leading to gut permeability.
Leaky gut Perturbation of the gut epithelium with structural alterations leading to increased permeability facilitating the translocation of pathobionts or beneficial microbes.
Gnotobiotic animals Animals living in a microbiologically defined environment. Most simplistic model is GF animals completely devoid of bacteria. Also GF animals colonized with known bacteria are defined as gnotobiotics.
16S rRNA sequencing
Sequencing technique used in microbiome research. 16S rRNA genes, which are bacteria specific, are amplified and then sequenced.
Shotgun DNA sequencing
Sequencing of all genetic information found in a sample. Allows taxonomic and functional analysis.
Sequencing read
In DNA sequencing, a read is an inferred sequence of base pairs (or base pair probabilities) corresponding to all or part of a single DNA fragment.
Alpha-diversity Measurement of the species diversity within a sample.
KEGG
The KEGG is a collection of databases dealing with genomes and biological pathways. The metagenome of a fecal sample can be compared with metabolic pathways (KEGG modules), to obtain information about the functional capacity of microbial community.
Prebiotics
Nondigestible food ingredients stimulating microbial species.
Probiotics
Live microorganisms for treatment.
GF indicates germ free; and KEGG, Kyoto Encyclopedia of Genes and Genomes.
We also tested whether probiotic treatment (Table 1) with L. murinus would induce mucosal tolerance with consequences for salt-sensitive blood pressure or multiple sclerosis symptoms. Preventive L. murinus treatment partially ameliorated both phenotypes in FVB/N and C57BL/6 mice with a similar reduction in Th17 cells. 13 Interestingly, Lactobacillus reuteri, 13 a species present in humans, reduced salt-sensitive hypertension, whereas Lactobacillus coryniformis 33 improved vascular function and insulin sensitivity in high fat-fed mice. These experimental data are in line with a meta-analysis focusing on the efficacy of probiotics, predominantly Lactobacillus-rich strategies on hypertension. The analysis revealed that high doses probiotics (≥10 11 colony-forming units) with life bacteria with treatment periods ≥2 month may lead to a reduction of blood pressure in individuals with hypertension. 34 We also performed an exploratory pilot study in healthy volunteers doubling the daily salt intake from 6 to 12 g by slow-release salt tablets. 13 In line with our experimental data, high salt challenge decreased Lactobacillus spp. in those people who were Lactobacillus spp. carriers at baseline. Furthermore, the subjects reacted with an increase in blood pressure and abundance of circulating Th17 cells. 13 To elucidate the molecular mechanism behind how L. murinus could affect Th17 differentiation, we followed a candidate approach focusing on a tryptophan metabolite. First, we demonstrated that germ-free mice monocolonized with L. murinus had high capacity to produce fecal and serum indole-3 lactic acid from tryptophan. Second, we found that high salt-fed mice had lower fecal indole-3 lactic acid content, which significantly increased under probiotic treatment. And ultimately, we could demonstrate in in vitro Th17 polarization experiments that indole-3 lactic acid dose dependently reduced the Th17 differentiation. 13 The role of sodium intake on microbiota-derived metabolite changes have also been investigated in a randomized placebo-controlled DASH (Dietary Approach to Stop Hypertension)-Sodium trial. 35 The study compared DASH diet (low in fat and high in protein, low-fat dairy, and fruits and vegetables) and control diet with 3 different sodium intake interventions (1150 versus 2300 versus 3450 mg sodium per day) in a crossover design. Eighty-two plasma metabolites from 6 different pathways were associated with sodium intake with a false discovery rate of <0.1. Seven metabolites derived from plant or food components including the tryptophan metabolite methyl-indole-3 acetate increased with reduced sodium levels. 35 Of note, hydroxyphenylpyruvate, a metabolite, which can stimulate indole metabolite formation via tryptophan aminotransferase followed the same pattern. 36 Further studies are needed to obtain a more comprehensive picture of the link between sodium, the microbiome and its metabolites, and host physiology and pathology.
Gut Microbiome Changes in Hypertension
Gut microbiome analysis in hypertension and hypertensionassociated organ damage has recently emerged as a new field. With newer sequencing techniques, microbiota can now be explored at the species level, permitting predictions of their functional impact on the host. 4, 37 For instance, Li et al 7 could show alterations in the gut microbiome of patients with hypertension and prehypertension, compared with healthy controls. Comparing 41 healthy controls, 56 subjects with prehypertension, and 99 patients with hypertension, their analysis revealed reduced alpha-diversity (Table 1) and gene richness in patients with hypertension as well as in patients with prehypertension. 7 The groups with hypertension and prehypertension also showed a higher number of patients with a Prevotella-rich enterotype (Table 1) , compared with the healthy control group. Most of the healthy subjects had a Bacteroides-dominant enterotype. 7 Upon fecal microbiota transfer from donors with hypertension and normotension into germ-free mice, the mice colonized with microbiota from patients with hypertension developed higher blood pressures. 7 Germ-free mice devoid of microbes are resistant to Ang (angiotensin) II-induced hypertension and vascular and cardiac damage. 38 Interestingly, bacteria known to be involved in the production of SCFA, such as the genera Faecalibacterium, Roseburia, and Bifidobacterium, were more abundant in healthy subjects. 7, 39 Kim et al 37 and Santisteban et al 40 provided experimental and clinical evidence that hypertension affects intestinal integrity. Of note, patients with hypertension showed taxonomic and functional gut microbiome changes with decreased butyrate production and increased inflammation. In addition, plasma zonulin, a marker for gut epithelial barrier dysfunction, is directly associated with systolic hypertension demonstrating a relationship between gut barrier, gut bacteria functions, and blood pressure in humans. 37 In Ang II-infused mice, butyrate improved gut permeability, which was accompanied by reduced blood pressure. 37 Yan et al 41 analyzed the gut microbiota of 60 patients with hypertension and 60 matched healthy subjects. They confirmed the reduced alpha-diversity and gene richness of patients with hypertension described by Li et al. 7 In their cohort, Faecalibacterium and Roseburia were similarly enriched in the healthy controls, compared with subjects with hypertension. Interestingly, the KEGG (Table 1) functional annotation of these metagenomes (Table 1) confirmed a depletion of genes relevant for SCFA synthesis in patients with hypertension. Similar features have also been found in the gut microbiota of spontaneous hypertensive rats, compared with healthy Wistar Kyoto rats. Spontaneous hypertensive rats exhibited a reduced alphadiversity and gene richness. 42 The percentage of sequencing reads (Table 1) from SCFA-producing bacteria in the 16S sequencing was reduced in spontaneous hypertensive rats and in Ang II-infused rats, compared with controls. 42 Yang et al 42 also describe a reduction in gene richness and alpha-diversity in a small set of patients with hypertension compared with matched healthy controls. Their study was limited in the resolution of bacterial taxonomy, because of the 16S sequencing technique the authors used. Nonetheless, their data provided the first indirect evidence for the role of SCFA production in experimental and clinical hypertension. Hypertension is the main risk factor for cardiovascular disease, outflanking smoking, blood sugar, blood lipids, and even global warming and diesel exhaust. 43 There are several mechanisms linking hypertension and atherosclerotic cardiovascular disease. Hypertension 44 and atherosclerosis 45, 46 are characterized by a similar chronic inflammatory state. Another link is the endothelial dysfunction found in both diseases. By different mechanisms, hypertension causes endothelial dysfunction, a key feature in the development of atherosclerosis. 47 Karlsson et al 48 compared the gut microbiome of 12 patients with symptomatic plaques of the carotid artery to the microbiome of 10 healthy control subjects. Ten of 12 patients with symptomatic atherosclerosis in this study had hypertension. Again, healthy subjects more commonly had a Bacteroides-dominant enterotype than the patients with atherosclerotic cardiovascular disease. Importantly, an enzyme relevant for the synthesis of the SCFA butyrate, butyrate-acetoacetate Coenzyme A-transferase, was inversely correlated with the inflammation marker hsCRP (highly sensitive C-reactive protein). 48 As in the hypertensive microbiome discussed above, Roseburia were decreased in atherosclerotic cardiovascular disease patients compared with healthy controls. In a larger study investigating the gut microbiota of 218 atherosclerotic cardiovascular disease patients compared with 187 healthy subjects, changes in bacterial diversity and richness were not detected; however, the potential to produce the SCFA butyrate was reduced.
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SCFA Affect Host Physiology
SCFA are produced by bacterial fermentation of nondigestible polysaccharides, also termed resistant starches or fiber in daily parlance. 50 Prebiotics such as fibers (Table 1 ) affect the microbiome. Various bacteria, as mentioned above, can produce SCFA. 39 SCFA are defined as fatty acids harboring 1 to 6 carbon atoms. Acetate, propionate, and butyrate are resorbed from the intestinal compartment by the host and can be found in measurable concentrations in peripheral blood. 51 SCFA influence the host physiology in different cell types and organs. Particularly, butyrate regulates intestinal cell proliferation and intestinal barrier function. 52 Interestingly, SCFA also influence innate and adaptive immunity. 53 SCFA can reduce the activation of neutrophil and classically activated macrophages including their production of inflammatory cytokines. 54, 55 SCFA also influence the adaptive immune system, especially CD4 + T cells. Propionate and butyrate can induce Tregs in vivo and the in vitro differentiation of naive T cells into Treg. [56] [57] [58] In vitro differentiation of effector T cells is also influenced by acetate, propionate, and butyrate. SCFA increased the number of effector T cells but also induced a regulatory, IL-10 producing, phenotype. 57 In general, SCFA induce a rather anti-inflammatory immune phenotype in the host.
Although the literature for the mode of action of SCFA is still inconclusive, some mechanistic studies suggest that SCFA in general and butyrate in particular inhibit HDAC (histone deacetylases). 59 SCFA were also shown to have a high affinity to the G-protein receptors GPR41 and GPR43. [60] [61] [62] Already in 1991, Nutting et al 63 observed a dose-dependent vasorelaxant effect of the SCFA acetate, propionate, and butyrate. More recently, Pluznick et al 64 showed that the SCFA acetate and propionate influence blood pressure regulation in 2 opposing manners. The kidney expresses olfactory receptors, making it a smelling rather than a smelly organ. The olfactory receptor 78 (Olfr78) is expressed in the kidney and shows a high affinity to acetate and propionate. 64 On the one hand, propionate binding to the receptor mediates a renin release leading to a blood pressure increase in WT mice and a hypotensive response in Olfr78 gene-deleted mice. 64 On the other hand, propionate also binds to GPR41, which is also expressed in the endothelium leading to a hypotensive response which is abrogated in GPR41-absent mice. 64 Further studies investigating the role of GPR41 on blood pressure regulation showed that 6-month-old GPR41 gene-deleted mice develop isolated systolic hypertension with increased vascular fibrosis, increased pulse wave velocity, and cardiac hypertrophy compared with wild-type littermates. 65 Taken together, SCFA influence blood pressure response dependent on different GPRs and thereby regulate blood pressure. SCFA seem to be a direct link between the microbiota and the blood pressure regulation.
SCFA in Hypertension and Cardiovascular Disease
As noted above, SCFA are influencing the host in several compartments relevant for hypertension and hypertensionassociated organ damage. Blood pressure regulation, inflammation, and HDAC were shown to play a major role in hypertension. 66, 67 As a result, we and others have pursued the hypothesis of ameliorating hypertensive organ damage with supplementation of different SCFA. Marques et al 68 provided evidence for the importance of fiber and acetate treatment in the pathogenesis of cardiovascular disease and renal disease and propose a gut-kidney-heart axis. Deoxycorticosterone acetate salt-treated uninephrectomized mice fed the highfiber diet (73% fiber) showed a higher abundance of acetateproducing bacteria than normal fiber (48% fiber) with lower blood pressure, less cardiac hypertrophy, and reduced fibrosis. Interestingly, acetate treatment in normal fiber-fed animals in addition to the protective effects on blood pressure and cardiac damage also reduced renal fibrosis. 68 Mice fed with SCFA exhibited changes in the gut microbiome in parts comparable to the fiber-induced changes, for instance, acetate-producing bacteria. 68 Transcriptomic analysis of renal and cardiac tissue revealed a large overlap in genes regulated in high fiber-fed mice and acetate-fed mice. 68 We recently tested the properties of oral propionate treatment in hypertensive mice, with and without atherosclerosis. 69 We used an outbred strain called NMRI and apolipoprotein E gene-deleted C57BL/6 mice, which were infused with Ang II for 2 and 4 weeks, respectively. 69 Propionate treatment decreased systemic and local inflammatory response, cardiac hypertrophy and fibrosis, and blood pressure in both models, an effect, which was lipid independent in apoE-deficient mice. 69 Besides the overall reduction of effector memory T cells, we also observed a decrease in proinflammatory Th17 cells defined as IL-17A + and IL-10 − . The therapeutic effects of propionate in the NMRI model were mediated by Tregs and were absent after Treg depletion. 69 Taken together, high fiber intake and SCFA supplementation improve hypertension and hypertensive target organ damage in different murine disease models. The precise mode of action still remains to be elucidated; however, the mechanism seems to be at least in part Treg dependent. In humans, a correlation between fiber intake and cardiovascular mortality exists. 70 Nevertheless, studies investigating SCFA or fiber supplementation in humans with prehypertension or hypertension are still lacking.
Pursuing risk factors for atherosclerosis, Kasahara et al 71 investigated the protective role of the gut microbiota in different mouse models of atherosclerosis. The authors observed an inverse correlation between the abundance of Roseburia, a known butyrate producer, and atherosclerotic lesion burden in mice with different genetic backgrounds. 71 The authors colonized apoE gene-deficient germ-free mice with a core microbial community as a control and the core community plus Roseburia intestinalis. Their purpose was to assess whether or not Roseburia influences atherosclerosis development. Indeed, R. intestinalis colonized animals showed higher cecal butyrate concentrations and less atherosclerotic plaques in the aortic root. 71 The expression of cytokines and the infiltration with monocytes in the aortic root of R. intestinalis colonized animals were also significantly decreased. The histone acetylation and energy metabolism of R. intestinalis colonized in the distal colon changed and improved the barrier function with less endotoxemia. Furthermore, the authors observed similar results upon treatment with tributyrin, a triglyceride naturally present in butter. Tributyrin is metabolized to butyrate by pancreatic lipases instead of by R. intestinalis colonization. 71 The role of inflammation and gut microbiome in atherosclerosis was investigated by Brandsma et al. 72 Gut microbiota from Casp1 (Caspase1)-knockout mice (KO) induces a more proinflammatory immune phenotype and worsens different inflammatory disease models. 73 The Casp1-KO gut microbiota showed a significant reduced abundance of SCFAproducing taxa with decreased cecal SCFA levels. 72 Upon transfer of Casp1-KO microbiota in low-density lipoprotein receptor-KO mice, the mice developed a more severe atherosclerosis with increased plasma levels of IL-10, IL-1β, IL-2, and IFN-γ. Furthermore, the number of circulating neutrophils and monocytes, as well as the number of neutrophils infiltrating into the aortic root were higher. 72 Myocardial infarction is a frequent consequence of atherosclerosis. Tang et al 74 investigated whether the gut microbiota have a protective effect in an animal model of myocardial infarction. Gut microbiota depletion with an antibiotic cocktail led to lower number of neutrophils and monocytes in the infarct area with decreased SCFA serum and feces levels accompanied by an increased mortality post-myocardial infarction. 74 Fecal microbiota transfer from healthy to antibiotic cocktail-treated mice ameliorated the phenotype. 74 Interestingly, supplementation with either a cocktail of SCFA or the increase of propionate by a Lactobacillus-based probiotic could also improve the phenotype. 74 Taken together, SCFA supplementation or supplementation of bacteria capable of producing SCFA shows a beneficial effect in different diseases associated with hypertension, whereby the anti-inflammatory effects of SCFA seem to play a central role (Figure) .
Drug-Microbe Interaction
Pharmacogenomics is a neologism addressing how genes might affect an individual's responses to drugs. More recently, the conceptual idea has been translated to the microbiome. Another tedious tongue twister, pharmacomicrobiomics, is concerned with the interaction between xenobiotics, or foreign compounds such as drugs, and the microbiome. A xenobiotic is a chemical substance found within an organism that is not naturally produced or expected to be present within the organism. Orally ingested drugs typically pass the upper and lower gastrointestinal tract and end up in the large intestine, where they contact and interact with the unique microbial ecosystem of the host. There are 3 major scenarios for how drug-microbe interactions could occur. First, drugs can affect the microbiome taxonomic composition and thereby its functional potential. Second, microbial transformation can inactivate or activate drugs with consequences for efficacy or toxicity to the host. Third, indirect microbial influence on the drug response may occur, where microbes interact with the host immune system or metabolisms and thereby affect drug bioavailability or response.
The fact that drugs can affect the microbiome taxonomic composition has only recently been appreciated. These interactions are summarized in Table 2 , discussed here, and were reviewed more extensively by others. 79 The drug classes most expected to impact the microbiome are antibiotics. 80 Treatment with antibiotics can lead to dysbiosis and ultimately, for example, to opportunistic overgrowth of Clostridium difficile. 80 Recently, neomycin and vancomycin have been shown to increase blood pressure in the genetic rat model of hypertension Dahl salt-sensitive rats, whereas the same antibiotics lowered or had no significant effect on blood pressure in the spontaneously hypertensive rats. These findings direct attention to the complexity of host genetics and microbiome on blood pressure. 81 Recent studies report that non-antibiotic drugs also may have similarly important impacts on the microbiome. The primary goal of the LifeLines DEEP project, initiated at the Genetics Department of the University Medical Center, Groningen, is to obtain insight in the relations between microbiome variation, genetic variation, and metabolic and phenotype variation. The LifeLines-DEEP population cohort identified 19 drugs or drug classes that are associated with altered gut microbiota composition, 76 whereas a similar study with the Belgian Flemish Gut Flora Project 75 reported 13. More recently, TwinsUK cohort researchers presented further gut microbiota association with 19 of the 52 medications in the cohort. 77 These drug classes include antibiotics, proton pump inhibitors, anticholinergic inhalers, paracetamol, opioids, osmotic laxatives, inflammatory bowel disease medications, therapeutic sex hormones, benzodiazepines, antidepressants, and antihistamines, although they do not distinguish between different drug compounds. In addition, nonsteroidal anti-inflammatory drugs 82 and atypical antipsychotics 83 have also been associated with changes in microbiome composition. Although it is unclear if and how these microbial changes as inferred from drug association studies impact the host, some studies already indicate clear causal impact, such as of the antidiabetic drug metformin and of proton pump inhibitors. Whereas metformin can affect the microbiome through SCFA production in patients with type 2 diabetes mellitus, 8 a finding later confirmed in the LifeLines-DEEP population cohort, 76, 84 treatment with proton pump inhibitors leads to a clear overrepresentation of oral microbes in the gut. 78, 85 This state of affairs may contribute why proton pump inhibitor users have a higher risk of enteric infections caused by C. difficile. 86 A more recent study using an in vitro high-throughput drug screen on 40 representative gut bacterial strains found that 24% of the 1197 compounds inhibited growth of at least 1 strain. These findings predict that further discoveries in this context of drug-bug interaction will be forthcoming. 87 The gut microbiome is also responsible for chemical transformations of drugs, which affects bioavailability and toxicity. 88 Currently, over 30 drugs have been identified as substrates for intestinal bacteria, a topic that has recently been reviewed extensively. 89, 90 Gut microbiome indirectly can impact drug bioavailability and therefore variability in therapeutic responses, as is the case of the lipid-lowering medication, simvastatin. Plasma concentrations of simvastatin are found to be directly correlated with levels of several secondary (microbially synthetized) bile acids that are regarded as important intestinal absorption agents and might influence the absorption of simvastatin. 91 Digoxin, a cardenolide used to treat heart failure and arrhythmia, can be also influenced by the human gut microbiota. 92 Haiser et al 93 have recently introduced an expanded model of digoxin pharmacokinetics. After colonization with distinct strains of Actinobacterium Eggerthella lenta, microbial interactions and the host diet act together to influence drug levels. 93 Another more recently described microbial impact on drug responsiveness is on the relationship between the gut microbiota and immunotherapy.
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Conclusions, Recommendations, and Future Directions
Despite accumulating evidence for microbiota-immune-host interaction and the interesting potential for personalized intervention strategies, several limitations should be taken into account. First and perhaps most important, much of the currently available data is based on association studies; causality between changes in the microbiome and in health or disease remains to be fully proven. Second, especially relevant to human microbiome research, are the limitations of fecal sample collection. Very recently, 2 landmark studies addressed the question on whether microbial signatures from fecal samples accurately reflect microbial gut mucosal composition. 96, 97 Analyzing mice and humans, the authors demonstrated that microbiome signatures from feces and swabs from the mucosal layer do not necessarily correspond. Thus, stool samples are an imperfect indicator of the upper intestinal milieu. In any event, extrapolations must be made with care. Finally, probiotic interventions also need to be regarded with caution. The aforementioned work by Elinav et al 96 showed that probiotics can interfere with the recovery antibiotic treatment. 96 More research is needed to better understand the local intestinal environment, focusing on which microbiota-derived metabolites are locally produced or present in each respective segment of the intestinal tract. To which extent these metabolites are taken up by the host and communicate with host cells needs to be further elucidated. Another interesting aspect requiring attention is whether or not microbially derived metabolites that only transiently pass through the gastrointestinal tract influence the host.
Understanding these interactions could allow the development of cardiovascular treatment concepts targeting the gut and its inhabitants in the future.
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